Is the oral histone deacetylase inhibitor LBH589 a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide?
LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect. Future trials with LBH589 should search for the specific characteristics of responding patients.
We found no evidence that acupuncture at the LI4, SP6 and sacral points could be harmful to the Wistar rat dams.